Luai Z. Hasoun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Luai Z. Hasoun has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad Riyad Alsayed
Applied Science Private University, Amman, Jordan, Jordan
1 shared publication - Heba A. Khader
Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, Zarqa 13133, Jordan
1 shared publication - Mohanad Al-Darraji
Department of Pharmaceutical Chemistry & Pharmacognosy, Applied Science Private University, Amman, Jordan, Jordan
1 shared publication - Mohannad Al-Qaiseiah
Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman 11733, Jordan
1 shared publication - Muath Alsarafandi
Islamic University of Gaza, Gaza, Palestine, Palestine
1 shared publication - Mustafa Al-Bayati
Applied Science Private University, Amman, Jordan, Jordan
1 shared publication
Latest Publications
- Open Access
- 12 November 2026
- Published by MDPI AG in Preprints.org
Modern Strategies in Cancer Therapy: From Chemotherapy to Precision Oncology
Cancer remains one of the leading causes of morbidity and mortality worldwide, necessitating continuous advances in therapeutic strategies to improve treatment efficacy and patient outcomes. Over recent decades, cancer management has evolved from conventional cytotoxic approaches toward more sophisticated, individualized interventions that target specific molecular alterations and harness the immune system. This review provides a comprehensive overview of the paradigm shift in cancer treatment, tracing the evolution from conventional chemotherapy to modern precision oncology and immunotherapy. We examine traditional diagnostic staging and highlight the integration of liquid biopsies and advanced biosensor technologies for real-time, non-invasive clinical monitoring. The review explores the mechanistic pillars of cell cycle-specific and non-specific chemotherapeutic agents, alongside the complex multidrug resistance pathways and metabolic rewiring that drive chemoresistance. We also evaluate the growing efficacy of targeted treatments, including small-molecule kinase inhibitors and antibody-drug conjugates, and detail the transformative clinical impact of immune checkpoint inhibitors, CAR-T cell therapies, and therapeutic vaccines. Emphasizing personalized medicine, we discuss the critical role of pharmacogenomics, biomarker-guided therapies, and the integration of artificial intelligence and quantitative systems pharmacology in optimizing dosing. Finally, we address future directions, including CRISPR-engineered cellular therapies and the modulation of the hypoxic tumor microenvironment using natural phytochemicals.
- 12 November 2026
- Published by MDPI AG in Preprints.org
Open AccessModern Strategies in Cancer Therapy: From Chemotherapy to Precision Oncology
Cancer remains one of the leading causes of morbidity and mortality worldwide, necessitating continuous advances in therapeutic strategies to improve treatment efficacy and patient outcomes. Over recent decades, cancer management has evolved from conventional cytotoxic approaches toward more sophisticated, individualized interventions that target specific molecular alterations and harness the immune system. This review provides a comprehensive overview of the paradigm shift in cancer treatment, tracing the evolution from conventional chemotherapy to modern precision oncology and immunotherapy. We examine traditional diagnostic staging and highlight the integration of liquid biopsies and advanced biosensor technologies for real-time, non-invasive clinical monitoring. The review explores the mechanistic pillars of cell cycle-specific and non-specific chemotherapeutic agents, alongside the complex multidrug resistance pathways and metabolic rewiring that drive chemoresistance. We also evaluate the growing efficacy of targeted treatments, including small-molecule kinase inhibitors and antibody-drug conjugates, and detail the transformative clinical impact of immune checkpoint inhibitors, CAR-T cell therapies, and therapeutic vaccines. Emphasizing personalized medicine, we discuss the critical role of pharmacogenomics, biomarker-guided therapies, and the integration of artificial intelligence and quantitative systems pharmacology in optimizing dosing. Finally, we address future directions, including CRISPR-engineered cellular therapies and the modulation of the hypoxic tumor microenvironment using natural phytochemicals.